Self-inactivating alpharetroviral vectors with a split-packaging design.
Accidental insertional activation of proto-oncogenes and potential vector mobilization pose serious challenges for human gene therapy using retroviral vectors. Comparative analyses of integration sites of different retroviral vectors have elucidated distinct target site preferences, highlighting vectors based on the alpharetrovirus Rous sarcoma virus (RSV) as those with the most neutral integration spectrum. To date, alpharetroviral vector systems are based mainly on single constructs containing viral coding sequences and intact long terminal repeats (LTR). Even though they are considered to be replication incompetent in mammalian cells, the transfer of intact viral genomes is unacceptable for clinical applications, due to the risk of vector mobilization and the potentially immunogenic expression of viral proteins, which we minimized by setting up a split-packaging system expressing the necessary viral proteins in trans. Moreover, intact LTRs containing transcriptional elements are capable of activating cellular genes. By removing most of these transcriptional elements, we were able to generate a self-inactivating (SIN) alpharetroviral vector, whose LTR transcriptional activity is strongly reduced and whose transgene expression can be driven by an internal promoter of choice. Codon optimization of the alpharetroviral Gag/Pol expression construct and further optimization steps allowed the production of high-titer self-inactivating vector particles in human cells. We demonstrate proof of principle for the versatility of alpharetroviral SIN vectors for the genetic modification of murine and human hematopoietic cells at a low multiplicity of infection.
Suerth
Julia D
JD
Experimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.
Maetzig
Tobias
T
Galla
Melanie
M
Baum
Christopher
C
Schambach
Axel
A
D001355:Alpharetrovirus / Q000235:genetics / Q000502:physiology*; D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D011401:Promoter Regions, Genetic; D012367:RNA, Viral / Q000235:genetics; D020079:Terminal Repeat Sequences / Q000235:genetics*; D019076:Transgenes; D019065:Virus Assembly
D012367:RNA, Viral
Gene Ther. 2001 Mar;8(6):477-86
11313827
Cell. 2002 Aug 23;110(4):521-9
12202041
Expert Opin Biol Ther. 2009 Nov;9(11):1427-36
19743892
J Virol. 1998 Nov;72(11):8463-71
9765382
Hum Gene Ther. 2007 Aug;18(8):691-700
17655493
J Clin Invest. 2008 Sep;118(9):3143-50
18688286
J Virol. 1982 Nov;44(2):725-30
6183452
J Virol. 2004 Aug;78(16):8421-36
15280451
J Virol. 1996 Oct;70(10):6642-52
8794299
J Exp Med. 1992 Oct 1;176(4):1125-35
1383375
Blood. 2003 Dec 1;102(12):3934-7
12881303
PLoS Biol. 2004 Aug;2(8):E234
15314653
Methods Cell Biol. 1994;43 Pt A:99-112
7823872
Mol Ther. 2006 Feb;13(2):391-400
16226060
J Clin Invest. 2008 Sep;118(9):3132-42
18688285
Mol Ther. 2009 Nov;17(11):1919-28
19672245
J Virol. 1995 Dec;69(12):7541-7
7494260
J Virol. 1987 Oct;61(10):3004-12
3041020
J Virol. 1983 Dec;48(3):667-75
6313966
EMBO J. 1985 Apr;4(4):949-56
2990916
Gene Ther. 2010 Mar;17(3):400-11
19847204
Blood. 2006 Oct 15;108(8):2545-53
16825499
Gene Ther. 2004 Jun;11(11):879-81
15057265
Mol Ther. 2008 Sep;16(9):1617-23
18578011
Mol Ther. 2008 Mar;16(3):590-8
18180772
Gene Ther. 2000 Jun;7(12):1063-6
10871756
Exp Hematol. 2006 May;34(5):588-92
16647564
J Virol. 2002 Feb;76(3):1488-95
11773421
Folia Biol (Praha). 2004;50(3-4):107-19
15373344
Cell. 1988 Nov 4;55(3):447-58
2846182
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Blood. 2002 Aug 1;100(3):823-32
12130492
Virology. 1984 Jul 15;136(1):89-99
6330999
J Virol. 2009 Jan;83(1):283-94
18945765
DNA Res. 2001 Oct 31;8(5):221-6
11759842
J Virol. 2000 Nov;74(22):10822-6
11044131
J Virol. 1996 Jun;70(6):3834-43
8648719
J Mol Biol. 1998 Nov 27;284(2):205-25
9813113
Gene Ther. 2006 Apr;13(7):641-5
16355114
Science. 2003 Jun 13;300(5626):1749-51
12805549
Mol Ther. 2008 Apr;16(4):718-25
18334985
Genomics. 2004 Jan;83(1):76-84
14667811
Nucleic Acids Res. 1995 Feb 25;23(4):628-33
7899083
J Clin Invest. 2009 Apr;119(4):964-75
19307726
J Virol. 1998 Dec;72(12):9873-80
9811723
Gene Ther. 2006 Nov;13(21):1524-33
16763662